Telehealth & Digital Health

The creator economy has mastered ROI-driven engagement. Can healthcare use its AI-powered playbook to improve patient outcomes and combat misinformation?

An Atlanta clinic's top award highlights a market shift toward minimally invasive fibroid treatment and a crucial fight for health equity in women's care.

A landmark demonstration of 'unhackable' quantum communication on a live network signals a paradigm shift for protecting sensitive healthcare data.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Dr. Timothy Lubenow's move from a top university to a community clinic highlights a trend that's making advanced medical care more accessible.

A Pennsylvania health system is partnering with an online platform to fast-track nurses, a model that could be a blueprint for a nation in crisis.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

SS Innovations is betting its cost-efficient SSi Mantra robot can break into the U.S. market. Will affordability democratize the operating room?

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A bioengineering firm is tapping deceased donors for bone marrow, promising to end shortages and improve outcomes. Is this the future of transplant medicine?

Abbott launches two new Ensure shakes, using science and tech to frame muscle health as the key to a longer, stronger life. Is protein the new longevity drug?